tiprankstipranks
Advertisement
Advertisement

CORT Stock Latest News

Midday Fly By: Microsoft reports sharp Q4 beat, Meta misses on earnings
The FlyMidday Fly By: Microsoft reports sharp Q4 beat, Meta misses on earnings
60m ago
BE
MA
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
PremiumRatings
Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged
2h ago
CORT
Corcept Therapeutics price target raised to $161 from $150 at Canaccord
PremiumThe Fly
Corcept Therapeutics price target raised to $161 from $150 at Canaccord
6h ago
CORT
Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler
PremiumThe Fly
Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler
6h ago
CORT
Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
PremiumThe Fly
Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
7h ago
CORT
Corcept Therapeutics Raises 2026 Revenue Outlook on Momentum
PremiumCompany AnnouncementsCorcept Therapeutics Raises 2026 Revenue Outlook on Momentum
21h ago
8K
CORT
Corcept Therapeutics reports Q2 EPS 36c, consensus 5c
Premium
The Fly
Corcept Therapeutics reports Q2 EPS 36c, consensus 5c
21h ago
CORT
Corcept Therapeutics price target raised to $150 from $135 at Canaccord
Premium
The Fly
Corcept Therapeutics price target raised to $150 from $135 at Canaccord
1d ago
CORT
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
PremiumThe Fly
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
3d ago
CORT
Is CORT a Buy, Before Earnings?
PremiumPre-Earnings
Is CORT a Buy, Before Earnings?
3d ago
CORT
Corcept Resubmits FDA Application for Relacorilant in Cushing’s
PremiumCompany Announcements
Corcept Resubmits FDA Application for Relacorilant in Cushing’s
1M ago
8K
CORT
Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome
PremiumThe Fly
Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome
1M ago
CORT
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
PremiumMarket NewsMega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
2M ago
EE
GH
Corcept announces presentation of new data from Catalyst, Momentum trials
Premium
The Fly
Corcept announces presentation of new data from Catalyst, Momentum trials
2M ago
CORT
Corcept Faces Amended Qui Tam Complaint After DOJ Exit
Premium
Company Announcements
Corcept Faces Amended Qui Tam Complaint After DOJ Exit
2M ago
8K
CORT
Corcept stockholders approve expanded incentive plan and board
PremiumCompany Announcements
Corcept stockholders approve expanded incentive plan and board
2M ago
8K
CORT
Corcept Therapeutics price target raised to $135 from $110 at Canaccord
PremiumThe Fly
Corcept Therapeutics price target raised to $135 from $110 at Canaccord
2M ago
CORT
Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright
PremiumThe Fly
Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright
2M ago
CORT
Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant
PremiumThe Fly
Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant
2M ago
CORT
Corcept Therapeutics upgraded to Buy from Neutral at UBS
PremiumThe FlyCorcept Therapeutics upgraded to Buy from Neutral at UBS
3M ago
CORT
Corcept Therapeutics upgraded to Buy from Neutral at UBS
Premium
The Fly
Corcept Therapeutics upgraded to Buy from Neutral at UBS
3M ago
CORT
Corcept Therapeutics Signals Big Growth After Key Wins
Premium
Company Announcements
Corcept Therapeutics Signals Big Growth After Key Wins
3M ago
CORT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >